Stockreport

Definium Therapeutics Reports Full-Year 2025 Financial Results and Business Updates [Yahoo! Finance]

Definium Therapeutics, Inc. - Common Shares  (DFTX) 
PDF Voyage (Phase 3 GAD) approximately 80% enrolled; no change in sample size required; topline readout anticipated in early 3Q 2026 Panorama (Phase 3 GAD) enrollment on [Read more]